EPS3.2 Dipeptidyl-peptidase IV (DPP4) levels in cystic fibrosis

Targeting Dipeptidyl Peptidase IV (CD26)

Tackling dipeptidyl peptidase IV in neurological disorders

Dipeptidyl peptidase IV (DPP-IV) is a serine protease best known for its role in inactivating glucagon-like peptide-1 (GLP-1), pituitary adenylate cyclase-activating polypeptide (PACAP) and glucose-dependent insulinotropic peptide (GIP), three stimulators of pancreatic insulin secretion with beneficial effects on glucose disposal. Owing to the relationship between DPP-IV and these peptides, inh...

Cd26/Dipeptidyl Peptidase IV in Context

C D26, the T cell activation molecule, is a 110-kD gly-coprotein that is also present on epithelial cells of various tissues, including the liver, kidney, and intestine. CD26 possesses a known dipeptidyl peptidase (DPP)IV activity in its extracellular domain (1). A paper by Wesley et al. in this issue indicates a possible role for CD26/DPPIV in suppressing malignant transformation of melanocyte...

Dipeptidyl Peptidase IV and Incident Diabetes

OBJECTIVE Dipeptidyl peptidase IV (DPP-IV) is not only important in beta-cell function but also has proinflammatory actions. We aimed to investigate whether it could act as a link between low-grade chronic inflammation and diabetes. RESEARCH DESIGN AND METHODS Using a case-cohort design, we followed 546 middle-aged individuals who developed diabetes and 538 who did not over approximately 9 ye...

Dipeptidyl peptidase IV inhibitors and diabetes therapy.

Current type 2 diabetes therapies are mainly targeted at stimulating pancreatic beta-cell secretion and reducing insulin resistance. A number of alternative therapies are currently being developed to take advantage of the actions of the incretin hormones Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP). These hormones are released from the small intestine i...